Handgretinger Rupert, Kurtzberg Joanne, Egeler R Maarten
Department of Hematology/Oncology and General Pediatrics, Children's University Hospital, Hoppe-Seyler-Strasse 1, Tuebingen, Germany.
Pediatr Clin North Am. 2008 Feb;55(1):71-96, x. doi: 10.1016/j.pcl.2007.10.013.
Allogeneic stem cell transplantation (SCT) is the only curative approach for many patients with advanced or high-risk leukemia. Advances in supportive care and management of graft-versus-host disease have resulted in improvements in outcomes of related and unrelated donor SCT, creating controversies as to which strategy might be the optimal therapy for individual patients. This article discusses the indications and donor selection strategies for SCT in patients with malignant hematologic disease.
异基因干细胞移植（SCT）是许多晚期或高危白血病患者的唯一治愈方法。支持治疗和移植物抗宿主病管理方面的进展已使相关和无关供体SCT的疗效得到改善，这引发了关于哪种策略可能是个体患者最佳治疗方法的争议。本文讨论了恶性血液病患者SCT的适应证和供体选择策略。
Zotero 插件